Laurion Capital Management LP - LINEAGE CELL THERAPEUTICS IN ownership

LINEAGE CELL THERAPEUTICS IN's ticker is LCTX and the CUSIP is 53566P109. A total of 116 filers reported holding LINEAGE CELL THERAPEUTICS IN in Q1 2023. The put-call ratio across all filers is 0.01 and the average weighting 0.1%.

Quarter-by-quarter ownership
Laurion Capital Management LP ownership history of LINEAGE CELL THERAPEUTICS IN
ValueSharesWeighting
Q3 2023$1,341,036
-51.6%
1,136,471
-42.2%
0.01%
-50.0%
Q2 2023$2,772,408
-22.3%
1,966,247
-17.3%
0.02%
-33.3%
Q1 2023$3,566,910
+28.2%
2,377,9400.0%0.02%
+84.6%
Q4 2022$2,782,190
+3.5%
2,377,9400.0%0.01%
-18.8%
Q3 2022$2,687,000
-29.8%
2,377,940
-1.8%
0.02%
-72.9%
Q2 2022$3,827,000
+34690.9%
2,422,367
+19316.2%
0.06%
Q2 2020$11,00012,4760.00%
Other shareholders
LINEAGE CELL THERAPEUTICS IN shareholders Q1 2023
NameSharesValueWeighting ↓
BROADWOOD CAPITAL INC 34,935,485$39,477,0003.01%
Raffles Associates 2,080,536$2,351,0002.51%
Defender Capital, LLC. 5,184,035$5,862,0002.30%
Prescott General Partners LLC 1,851,851$2,093,0000.16%
DAFNA Capital Management LLC 140,000$158,0000.04%
Fort Sheridan Advisors LLC 83,931$95,0000.03%
Long Focus Capital Management, LLC 215,000$243,0000.02%
XTX Topco Ltd 72,807$82,0000.02%
Ergoteles LLC 490,895$555,0000.02%
Beirne Wealth Consulting Services, LLC 45,000$51,0000.02%
View complete list of LINEAGE CELL THERAPEUTICS IN shareholders